Although CCR5 may be important in regulating insulin sensitivity, its level does not change in rodent models of STZ-induced diabetic neuropathy; however, RAP-103 treatment decreases the mRNA level of CCR5 and alleviates tactile and thermal hypersensitivity, suggesting that CCR5 participates in nociceptive transmission in the chronic pain state. The gene discussed is CCR5; the disease is diabetic neuropathy.